Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Similarities Between AI and Psychedelics

Feb 15 • 4 min read

It appears that society is increasingly embracing solutions whose inner workings remain a mystery, a trend underscored by the rising adoption of cutting-edge technologies like artificial intelligence (AI) and traditional remedies for ennui such as psychedelics. In the United States, the allure of psychedelics is on an upward trajectory. A 2021 study by the University…

Unveiling the Mysteries of the Mind: A Landmark Event in New Orleans

Feb 14 • 3 min read

From February 16th to 18th, the vibrant city of New Orleans will play host to one of the most anticipated events in the field of psychology. It’s the second annual International Society for Research on Psychedelics conference! This gathering promises to be a melting pot of ideas, showcasing the latest advancements and innovative research in…

New Mexico Takes Bold Steps Towards Psilocybin Therapy Research

Feb 14 • 4 min read

In a remarkable show of bipartisan unity, a New Mexico Senate committee has recently cast a unanimous vote in favor of a resolution aimed at delving into the therapeutic potential of psilocybin mushrooms. This initiative marks a significant stride towards understanding and potentially integrating this psychedelic into therapeutic settings. Spearheaded by Senate Minority Whip Craig…

A Doctor is Suing the DEA To Treat Terminally Ill Patients with Psilocybin

Feb 12 • 3 min read

Dr. Sunil Aggarwal, alongside the Advanced Integrative Medical Science Institute (AIMS) he helped establish, is challenging the Drug Enforcement Administration (DEA) in court. Their lawsuit arises from the DEA’s refusal to permit the use of psilocybin for treating patients facing the end stages of their lives, despite Washington state’s “Right-to-Try” law, which allows for the…

The FDA Accepts MDMA for PTSD Therapy’s New Drug Application

Feb 12 • 2 min read

The U.S. Food and Drug Administration (FDA) has recently accepted a groundbreaking New Drug Application (NDA) submitted by Lykos Therapeutics for MDMA-assisted therapy in the treatment of Post-Traumatic Stress Disorder (PTSD). This pivotal moment signifies a crucial step forward in the potential adoption of psychedelic-assisted treatments within conventional medical practices. Originating from the Multidisciplinary Association…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354